George Rho
Research analyst, long/short equity, special situations, arbitrage

Sarepta Therapeutics: Irrational Exuberance

Just a year ago, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), then known as AVI BioPharma, was a small, little-known developmental stage biopharmaceutical company. It had an undistinguished 32-year history, characterized by year after year of red ink and no marketable product. At the end of last June, the money-losing enterprise had only $16.1 million in working capital, a stock that was trading at 63 cents a share, and a market capitalization of $85 million.

So much has happened since then beyond the cosmetic adoption of a new name. This includes a relocation of operations, changes in executive leadership, and a substantial fortification of the balance sheet. Perhaps most significant, the biotech now sports a market capitalization that's north of $1...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details